Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Antex Biologics (ANTX) -- Ignore unavailable to you. Want to Upgrade?

To: Richard Peterson who wrote (672)	2/10/1998 6:42:00 AM
From: RBM	Read Replies (2) \| Respond to of 1476

Richard, I thought that the requirement was to make companies report, not to have them trade over a dollar...haven't really seen to much on it lately, maybe you could clarify. TIA Rob

To: Richard Peterson who wrote (672)	2/18/1998 2:42:00 PM
From: John R Resseger	Read Replies (1) \| Respond to of 1476

From last years annual report Campylobacter Campylobacter is a leading cause of diarrheal disease worldwide--over 400 million cases annually. The Company has entered into a Cooperative Research and Development Agreement ("CRADA") with the United States Navy which has as its objective the development of a safe and effective vaccine to prevent diarrhea caused by enteropathogenic Campylobacter jejuni. The Company has developed and produced a whole cell vaccine utilizing its know-how in NST. Two successful clinical trials have been completed. The first was a Phase I clinical study which showed the safety and immunogenicity of the formalin-inactivated (killed) Campylobacter whole cell vaccine preparation. The second trial tested the safety and immunogenicity of a killed Campylobacter whole cell vaccine in combination with a mucosal adjuvant. Data from this second study are being analyzed; however, preliminary results indicated that the combination is safe and immunogenic. As a result of these successful Phase I clinical studies, Phase II and III clinical studies are being planned. These potential vaccine products have been licensed for use in humans to SmithKline Beecham through MCHV for further development and possible commercialization. Uses other than as human vaccines are available for other collaborations that may be entered into by the Company. See "Strategy for Commercial Development."